CyBorD: Stellar response rates in AL amyloidosis

Research output: Contribution to journalArticlepeer-review


In two independent retrospective studies, Mikhael et al and Venner et al report unprecedentedly high hematologic response rates, 94% and 81%, including complete response (CR) in 71% and 42%, respectively, to the combination of cyclophosphamide-bortezomib-dexamethasone in patients with either naive or relapsed light chain (AL) amyloidosis.

Original languageEnglish
Pages (from-to)4343-4345
Number of pages3
Issue number19
Publication statusPublished - May 10 2012

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology


Dive into the research topics of 'CyBorD: Stellar response rates in AL amyloidosis'. Together they form a unique fingerprint.

Cite this